Patents Assigned to Incyte Pharmaceuticals, Inc.
  • Patent number: 7803373
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: September 28, 2010
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger T. Coleman, Olga Bandman, Craig G. Wilde
  • Publication number: 20070105171
    Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.
    Type: Application
    Filed: October 2, 2006
    Publication date: May 10, 2007
    Applicants: Incyte Pharmaceuticals, Inc., Genentech, Inc.
    Inventors: Olga Bandman, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Y. Tang, Purvi Shah
  • Publication number: 20070026449
    Abstract: The present invention provides a human sodium-dependent phosphate cotransporter (NAPTR) and polynucleotides which identify and encode NAPTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NAPTR and a method for producing NAPTR. The invention also provides for agonists, antibodies, or antagonists specifically for NAPTR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NAPTR for the treatment of diseases associated with the expression of NAPTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NAPTR. The invention also provides a method for treating disorders associated with decreased phosphate levels by administering NAPTR and a method for treating disorders associated with increased phosphate levels by administering antagonists to NAPTR.
    Type: Application
    Filed: September 25, 2006
    Publication date: February 1, 2007
    Applicant: Incyte Pharmaceuticals, Inc
    Inventors: Preeti Lal, Olga Bandman
  • Publication number: 20050181404
    Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.
    Type: Application
    Filed: January 27, 2005
    Publication date: August 18, 2005
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Y. Tang, Purvi Shah
  • Publication number: 20050042724
    Abstract: The present invention provides a human sodium-dependent phosphate cotransporter (NAPTR) and polynucleotides which identify and encode NAPTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NAPTR and a method for producing NAPTR. The invention also provides for agonists, antibodies, or antagonists specifically for NAPTR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NAPTR for the treatment of diseases associated with the expression of NAPTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NAPTR. The invention also provides a method for treating disorders associated with decreased phosphate levels by administering NAPTR and a method for treating disorders associated with increased phosphate levels by administering antagonists to NAPTR.
    Type: Application
    Filed: June 25, 2004
    Publication date: February 24, 2005
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Olga Bandman
  • Patent number: 6855811
    Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: February 15, 2005
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Neil C. Corley, Y. Tom Tang, Purvi Shah
  • Publication number: 20040111674
    Abstract: Disclosed are methods, media and systems for graphically displaying computer-based biomolecular sequence information. Generally, biomolecular sequence information may be graphically depicted in a variety of different forms in accordance with the present invention. The sequence information may be composed of nucleotide or amino acid sequence information or both. The graphical depictions may be in several different formats providing different information relating to the sequences, and may be displayed in one or more screens of a computer user interface.
    Type: Application
    Filed: November 3, 2003
    Publication date: June 10, 2004
    Applicants: Incyte Genomics, Inc., Incyte Pharmaceuticals, Inc.
    Inventors: Alex George Koleszar, Frank D. Russo, Joe Don Heath, Stephanie F. Berry, Rachel J. Wright, Peter A. Covitz, Yvonne R. Boldt, Lee Crawford
  • Publication number: 20040086936
    Abstract: The invention provides a human preproneurotensin/neuromedin N (HPPN) and polynucleotides which identify and encode HPPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HPPN.
    Type: Application
    Filed: August 9, 2001
    Publication date: May 6, 2004
    Applicant: Incyte Pharmaceuticals, Inc
    Inventors: Preeti Lal, Purvi Shah, Neil C. Corley
  • Publication number: 20040024535
    Abstract: The present invention provides relational database systems for storing biomolecular sequence information together with biological annotations detailing the source of the sequence information, and associated reagent information. The acquisition, storage and access of reagent information associated with databased biomolecular sequence information is a particular advantage of the present invention. Such reagent information identifies genetic information and materials which may be made available to a user of the relational database system of the present invention for further application in research, therapeutic pharmaceutical development or other fields. The reagent information aspect of the present invention is preferably used in conjunction with a biomolecular sequence relational database system.
    Type: Application
    Filed: February 4, 2003
    Publication date: February 5, 2004
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Stephen E. Lincoln, Tod M. Klingler, Landes C. Wong, Scott R. Panzer, David M. Hodgson, Laura Y. Ito, Andrew D. Ament, Richard Cathcart, Helen E. Jolley, Ingrid E. Akerblom, Brian M. McKelligon, Mayank K. Thanawala
  • Publication number: 20030237110
    Abstract: The present invention provides purified, corn seedling-derived polynucleotides (cdps) which encode corn seedling-derived polypeptides (CDPs). The invention also provides for the use of cdps or their complements, oligonucleotides, or fragments in methods for determining altered gene expression, to recover regulatory elements, and to follow inheritance of desirable characteristics through hybrid breeding programs. The invention further provides for vectors and host cells containing cdps for the expression of CDPs. The invention additionally provides for (i) use of isolated and purified CDPs to induce antibodies and to screen libraries of compounds and (ii) use of anti-CDP antibodies in diagnostic assays.
    Type: Application
    Filed: August 6, 2001
    Publication date: December 25, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Raghunath V. Lalgudi, Laura Y. Ito, Bradley K. Sherman
  • Publication number: 20030170219
    Abstract: The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.
    Type: Application
    Filed: January 24, 2001
    Publication date: September 11, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Surya K. Goli, Purvi Shah
  • Publication number: 20030166847
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human leptin receptor gene-related protein (LRGRP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding LRGRP. The invention also provides for the use of substantially purified LRGRP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of LRGRP. Additionally, the invention provides for the use of antisense molecules to LRGRP in pharmaceutical compositions for treatment of diseases associated with the expression of LRGRP.
    Type: Application
    Filed: November 5, 2001
    Publication date: September 4, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Bernard Bailleul, A. Donny Strosberg, Ingrid E. Akerblom
  • Publication number: 20030166043
    Abstract: The present invention provides a novel human tubby homolog (NHT) and polynucleotides which identify and encode NHT. The invention also provides expression vectors, host cells, agonists, antibodies, or antagonists. The invention also provides methods for treating disorders associated with appetite and eating.
    Type: Application
    Filed: February 12, 2001
    Publication date: September 4, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Samuel T. Labrie, Preeti Lal, Lynn E. Murry
  • Publication number: 20030166199
    Abstract: The invention provides a human serine dehydratase homolog (SDHH) and polynucleotides which identify and encode SDHH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of SDHH.
    Type: Application
    Filed: August 8, 2001
    Publication date: September 4, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley, Karl J. Guegler, Chandra Patterson
  • Publication number: 20030147893
    Abstract: The present invention provides a novel human integral membrane (TMP-1) and polynucleotides which identify and encode TMP-1. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TMP-1 and a method for producing TMP-1. The invention also provides for agonists, antibodies, or antagonists specifically binding TMP-1, and their use, in the prevention and treatment of diseases associated with expression of TMP-1. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TMP-1 for the treatment of diseases associated with the expression of TMP-1. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TMP-1.
    Type: Application
    Filed: October 2, 2001
    Publication date: August 7, 2003
    Applicant: Incyte Pharmaceuticals, Inc
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Publication number: 20030118995
    Abstract: The present invention provides four human Rab and Rab-associated proteins (designated collectively as HRAB) and polynucleotides which identify and encode HRAB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRAB and a method for producing HRAB. The invention also provides for use of HRAB and agonists, antibodies, or antagonists specifically binding HRAB, in the prevention and treatment of diseases associated with expression of HRAB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRAB for the treatment of diseases associated with the expression of HRAB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRAB.
    Type: Application
    Filed: September 28, 2001
    Publication date: June 26, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young
  • Publication number: 20030119730
    Abstract: The invention provides two human phospholipid binding proteins (PLBP) and polynucleotides which identify and encode PLBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of PLBP.
    Type: Application
    Filed: June 11, 2001
    Publication date: June 26, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Publication number: 20030099612
    Abstract: The present invention provides a human microtubule-associated protein (hLC3) and the polynucleotides which identify and encode hLC3. The invention also provides genetically engineered expression vectors, host cells, and a method for producing hLC3. The invention also provides hLC3 as well as agonists, antibodies, and antagonists of hLC3, and the use thereof for the prevention and treatment of diseases associated with the expression of hLC3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding hLC3 for the treatment of diseases associated with the expression of hLC3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding hLC3.
    Type: Application
    Filed: July 12, 2001
    Publication date: May 29, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6553317
    Abstract: The present invention provides relational database systems for storing biomolecular sequence information together with biological annotations detailing the source of the sequence information, and associated reagent information. The acquisition, storage and access of reagent information associated with databased biomolecular sequence information is a particular advantage of the present invention. Such reagent information identifies genetic information and materials which may be made available to a user of the relational database system of the present invention for further application in research, therapeutic pharmaceutical development or other fields. The reagent information aspect of the present invention is preferably used in conjunction with a biomolecular sequence relational database system.
    Type: Grant
    Filed: March 4, 1998
    Date of Patent: April 22, 2003
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Stephen E. Lincoln, Tod M. Klingler, Landes C. Wong, Scott R. Panzer, David M. Hodgson, Laura Y. Ito, Andrew D. Ament, Richard Cathcart, Helen E. Jolley, Ingrid E. Akerblom, Brian M. McKelligon, Mayank K. Thanawala
  • Publication number: 20030044401
    Abstract: The present invention provides a human glutathione s-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.
    Type: Application
    Filed: February 14, 2001
    Publication date: March 6, 2003
    Applicant: Incyte Pharmaceuticals, Inc.
    Inventors: Surya K. Goli, Jennifer L. Hillman